Huart, CarolinePhilpott, Carl M.Altundag, AytugFjaeldstad, Alexander W.Frasnelli, JohannesGane, SimonHsieh, Julien W.Holbrook, Eric H.Konstantinidis, IordanisLandis, Basile N.Macchi, AlbertoMueller, Christian A.Negoias, SimonaPinto, Jayant M.Poletti, Sophia C.Ramakrishnan, Vijay R.Rombaux, PhilippeVodicka, JanWelge-Lüessen, AntjeWhitcroft, Katherine L.Hummel, Thomas2024-11-252024-11-252021Huart C, Philpott CM, Altundag A, et al. Systemic corticosteroids in coronavirus disease 2019 (COVID-19)-related smell dysfunction: an international view. Int Forum Allergy Rhinol. 2021;11(7):1041-1046. doi:10.1002/alr.22788https://hdl.handle.net/1805/44684The frequent association between coronavirus disease 2019 (COVID-19) and olfactory dysfunction is creating an unprecedented demand for a treatment of the olfactory loss. Systemic corticosteroids have been considered as a therapeutic option. However, based on current literature, we call for caution using these treatments in early COVID-19-related olfactory dysfunction because: (1) evidence supporting their usefulness is weak; (2) the rate of spontaneous recovery of COVID-19-related olfactory dysfunction is high; and (3) corticosteroids have well-known potential adverse effects. We encourage randomized placebo-controlled trials investigating the efficacy of systemic steroids in this indication and strongly emphasize to initially consider smell training, which is supported by a robust evidence base and has no known side effects.en-USPublisher PolicyCorticosteroidsCOVID‐19Olfaction disorderSARS‐CoV‐2SmellArticle